RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
China’s Tianhui Incubator of Technologies will join hands with Israel’s Oramed Pharmaceuticals to produce what is expected to become the world’s first oral insulin product to treat type 2 diabetes.
Tianhui has penned a technology licensing agreement with Oramed to bring the latter’s orally ingestible insulin capsules to the Chinese market in two years, the 21st Century Business Herald reported, citing Chairman Gao Xiaoming.
In November, Jerusalem-based Oramed made a breakthrough in its insulin capsules development — an area of research that global drug giants such as Novo Nordisk have abandoned, citing a lack of technology to make sure that the body absorbs a certain amount of insulin through the pills.
Hefei-based Tianhui has been in the insulin business for many years and has the industrial capacity to produce the capsules, it added.
Source: yicaiglobal.com
